共 50 条
Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay
被引:35
|作者:
Arredondo, Miguel
[1
]
Garrido, Carolina
[1
]
Parkin, Neil
[2
,3
]
Zahonero, Natalia
[1
]
Bertagnolio, Silvia
[2
]
Soriano, Vincent
[1
]
de Mendoza, Carmen
[1
]
机构:
[1] Hosp Carlos III, Dept Infect Dis, Madrid, Spain
[2] World Hlth Org, HIV Dept, Geneva, Switzerland
[3] Data First Consulting Inc, Menlo Pk, CA USA
关键词:
DRUG-RESISTANCE SURVEILLANCE;
DIFFERENT STORAGE-CONDITIONS;
QUANTITATIVE ASSAYS;
WHOLE-BLOOD;
SPECIMENS;
QUANTIFICATION;
DIAGNOSIS;
CAMEROON;
D O I:
10.1128/JCM.00418-11
中图分类号:
Q93 [微生物学];
学科分类号:
071005 ;
100705 ;
摘要:
Dried blood spots (DBS) may be a promising alternative specimen type to plasma for measuring the viral load (VL) in HIV-infected individuals in resource-limited settings. However, characterization of assay performance using DBS is incomplete. In this prospective study, the VL was measured in parallel using plasma and DBS specimens collected at the same time from 157 HIV-1-infected individuals. DBS were prepared by dispensing 50 mu l of blood onto filter paper cards and were stored desiccated at -20 degrees C. Nucleic acid extraction from plasma and DBS was performed automatically using the Abbott m2000sp instrument, and the VL was measured using the RealTime HIV-1 VL assay, which has a lower limit of detection of 40 HIV RNA copies/ml. The correlation between plasma and DBS results was good (R = 0.91; P < 0.001). The mean difference in the VL (DBS minus plasma) was 0.35 log copies (standard deviation [SD], 0.47 log copies). A total of 40 (26%) paired specimens had a difference of >0.5 log copy, and in 12 (7.8%) it was >1 log copy. the VL from DBS was measurable in 95.7% of specimens with a plasma VL of >2.74 log copies (550 HIV RNA copies/ml). In summary, the VL can reliably be measured using DBS with the Abbott RealTime HIV-1 assay. The estimated lower limit of detection of this automated methodology on DBS is 550 copies/ml, a threshold that may be acceptable for periodic VL monitoring in patients on antiretroviral therapy in resource-limited settings, where early detection of virologic treatment failure is often problematic.
引用
收藏
页码:569 / 572
页数:4
相关论文